Healx
Founded Year
2014Stage
Series C | AliveTotal Raised
$113.38MLast Raised
$47M | 7 mos agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
+453 points in the past 30 days
About Healx
Healx is a technology company focused on artificial intelligence (AI) drug discovery for rare disease treatment within the pharmaceutical industry. The company specializes in using AI to identify drug-disease relationships and accelerate the development of new therapies for rare conditions. Healx's approach aims to increase the scale and success rate of rare disease treatment development by repurposing known compounds and running multiple drug discovery programs in parallel. Healx was formerly known as Healx3. It was founded in 2014 and is based in Cambridge, United Kingdom.
Loading...
ESPs containing Healx
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The AI-derived small molecule drugs market leverages AI and machine learning to discover and develop novel small molecule therapeutics. Companies in this market combine physics-based AI algorithms, deep learning models, and generative AI with experimental validation to enable target identification, virtual screening, and lead optimization. Proprietary platforms integrate computational approaches w…
Healx named as Leader among 15 other companies, including Insilico Medicine, Recursion, and Schrodinger.
Healx's Products & Differentiators
Indication expansion
New rare or common disease predictions for human safe compounds. Our technology can be applied to marketed, development or shelved compounds. Healx performs prediction and early pharmacological validation of predictions.
Loading...
Research containing Healx
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Healx in 2 CB Insights research briefs, most recently on Aug 21, 2024.
Aug 21, 2024
The clinical trials tech market map
May 17, 2022 report
AI 100: The most promising artificial intelligence startups of 2022Expert Collections containing Healx
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Healx is included in 6 Expert Collections, including Artificial Intelligence.
Artificial Intelligence
9,504 items
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
Digital Health 50
150 items
The winners of the second annual CB Insights Digital Health 150.
Digital Health
11,329 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
AI 100
100 items
Drug Discovery Tech Market Map
221 items
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
AI in drug discovery
504 items
Companies using AI to advance therapeutic discovery, categorized into: platforms (primary product is software) and discovery engines (primary product is therapeutics). Additional funnel descriptions reflect how companies are applying AI.
Healx Patents
Healx has filed 11 patents.
The 3 most popular patent topics include:
- neurological disorders
- autism
- rare diseases
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
4/12/2019 | 2/28/2023 | Phosphodiesterase inhibitors, Lactams, Amines, Beta blockers, Piperazines | Grant |
Application Date | 4/12/2019 |
|---|---|
Grant Date | 2/28/2023 |
Title | |
Related Topics | Phosphodiesterase inhibitors, Lactams, Amines, Beta blockers, Piperazines |
Status | Grant |
Latest Healx News
Feb 25, 2025
The single-arm trial focuses on the therapy’s efficacy and safety in NF1 subjects with plexiform neurofibromas. Credit: S_L/Shutterstock. Healx has dosed the first subject in the open-label Phase II INSPIRE-NF1 trial to assess the efficacy and safety of HLX-1502 in individuals with neurofibromatosis type 1 (NF1), a rare genetic disorder that causes tumours to form along nerves. The single-arm trial focuses on oral investigational therapy’s efficacy and safety in NF1 subjects with plexiform neurofibromas (PNs), which are aggressive tumours that can lead to complications such as malignant transformation and functional impairments. Nearly 20 subjects in the US are being enrolled for the trial, which will concentrate on important outcome measures such as tolerability, pharmacokinetics, safety as well as tumour response rate. Last August, Healx received the US Food and Drug Administration (FDA) clearance for its investigational new drug application (IND) to begin the Phase II trial of HLX-1502. Healx CEO and co-founder Tim Guilliams said: “For too long, patients have had limited treatment options that come with serious trade-offs. HLX-1502 is being evaluated as a potential treatment for NF1, with the goal of providing an alternative to existing MEK inhibitors, which have known side effects. “If successful, this could mark the beginning of a paradigm shift in NF1 care—one that not only improves patient lives today but also paves the way toward a future where patients no longer have to choose between treatment effectiveness and quality of life.” Discovered using the company’s AI platform, HLX-1502 has gained an orphan drug, rare paediatric disease, and fast-track designations from the FDA. In April 2024, Healx signed an investment agreement with its long-term partner Children’s Tumor Foundation (CTF), which funds research aimed at developing treatments for individuals living with NF. CTF’s milestone-driven payments will support the progression of Healx’s neurofibromatosis programme, including HLX-1502. Sign up for our daily news round-up! Give your business an edge with our leading industry insights.
Healx Frequently Asked Questions (FAQ)
When was Healx founded?
Healx was founded in 2014.
Where is Healx's headquarters?
Healx's headquarters is located at 66-68 Hills Road, Cambridge.
What is Healx's latest funding round?
Healx's latest funding round is Series C.
How much did Healx raise?
Healx raised a total of $113.38M.
Who are the investors of Healx?
Investors of Healx include Jonathan Milner, Balderton Capital, Global Brain, Atomico, b2venture and 12 more.
Who are Healx's competitors?
Competitors of Healx include Aitia, Maya AI, Verge Genomics, Cyclica, BERG and 7 more.
What products does Healx offer?
Healx's products include Indication expansion and 3 more.
Who are Healx's customers?
Customers of Healx include Ovid Therapeutics.
Loading...
Compare Healx to Competitors
Aitia focuses on the development and application of Causal AI and Digital Twins in the pharmaceutical industry. The company's main services include the discovery of drugs for neurodegenerative disorders, oncology, and immunology by revealing hidden biological mechanisms of diseases and creating Digital Twins. It is used to discover novel therapies and accelerate research and development in various diseases such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, multiple myeloma, prostate cancer, and pancreatic cancer. It was founded in 2000 and is based in Cambridge, Massachusetts.
Insitro focuses on drug discovery and development. The company's main services involve the use of machine learning and throughput biology to predict successful paths for medicine creation. It aims to avoid costly failures in pharmaceutical research and development. Insitro primarily sells to the healthcare industry. It was founded in 2018 and is based in South San Francisco, California.
Atomwise develops machine learning-based discovery engines and uses artificial intelligence (AI)-based neural networks to help discover new medicines. It predicts drug candidates for pharmaceutical companies, start-ups, and research institutions and designs drugs using computational drug design. It was formerly known as Chematria. The company was founded in 2012 and is based in San Francisco, California.
Aria Pharmaceuticals operates as a preclinical-stage pharmaceutical company that focuses on the discovery and development of novel, small-molecule therapies in the pharmaceutical industry. The company's main service is the development of new treatments for complex and hard-to-treat diseases using its proprietary symphony platform, which combines biomedical data and artificial intelligence to increase the success rates of drug discovery. Aria Pharmaceuticals primarily serves the healthcare sector, specifically targeting areas where new therapies are most needed. It was founded in 2014 and is based in Palo Alto, California.
Standigm specializes in AI-driven drug discovery within the pharmaceutical industry. The company provides services, including target identification, lead generation, and optimization, as well as AI SaaS solutions for drug development. Standigm primarily serves sectors engaged in pharmaceutical research and drug development. It was founded in 2015 and is based in Seoul, South Korea.
BioMap focuses on leveraging artificial intelligence (AI) to advance life sciences. The company develops AI foundation models to understand and predict biological behaviors and creates task models for various life science applications, including therapeutic antibodies and industrial enzymes. BioMap primarily serves the biotechnology and pharmaceutical industries with its AI-driven solutions. It was founded in 2020 and is based in Palo Alto, California.
Loading...